FY2025 EPS Estimates for NextCure Lifted by HC Wainwright

NextCure, Inc. (NASDAQ:NXTC) – Investment analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for NextCure in a note issued to investors on Monday, November 17th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($5.93) per share for the year, up from their previous estimate of ($6.72). The consensus estimate for NextCure’s current full-year earnings is ($1.87) per share. HC Wainwright also issued estimates for NextCure’s Q4 2025 earnings at ($2.14) EPS, Q1 2026 earnings at ($1.88) EPS, Q2 2026 earnings at ($2.09) EPS, Q3 2026 earnings at ($2.33) EPS, Q4 2026 earnings at ($2.51) EPS, FY2026 earnings at ($8.81) EPS, FY2027 earnings at ($3.47) EPS, FY2028 earnings at ($3.34) EPS and FY2029 earnings at ($2.29) EPS.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($3.22) earnings per share for the quarter, beating the consensus estimate of ($4.06) by $0.84.

Several other research analysts also recently issued reports on NXTC. LADENBURG THALM/SH SH upgraded shares of NextCure from a “neutral” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of NextCure in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, NextCure currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

NextCure Stock Performance

Shares of NXTC stock opened at $10.00 on Wednesday. The company has a market capitalization of $26.80 million, a price-to-earnings ratio of -0.41 and a beta of 1.48. NextCure has a one year low of $2.69 and a one year high of $16.80. The company’s 50-day moving average is $7.92 and its 200 day moving average is $6.29.

Institutional Trading of NextCure

An institutional investor recently raised its position in NextCure stock. Pfizer Inc increased its stake in shares of NextCure, Inc. (NASDAQ:NXTC) by 29.7% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,891,763 shares of the company’s stock after purchasing an additional 433,213 shares during the period. NextCure makes up 0.2% of Pfizer Inc’s investment portfolio, making the stock its 17th largest holding. Pfizer Inc owned 6.74% of NextCure worth $909,000 as of its most recent filing with the Securities & Exchange Commission. 42.65% of the stock is currently owned by institutional investors.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.